Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Contribution

Plasma Pancreatic Polypeptide Response to Insulin-induced Hypoglycemia as a Marker for Defective Glucose Counterregulation in Insulin-dependent Diabetes Mellitus

  1. Neil H White,
  2. Ronald L Gingerich,
  3. Lucy A Levandoski,
  4. Philip E Cryer and
  5. Julio V Santiago
  1. Edward Mallinckrodt Department of Pediatrics and the Department of Medicine, Washington University School of Medicine St. Louis, Missouri
  1. Address reprint requests to Neil H. White, M.D., St. Louis Children's Hospital, P.O.Box 14871, St. Louis, Missouri 63178.
Diabetes 1985 Sep; 34(9): 870-875. https://doi.org/10.2337/diab.34.9.870
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Defective glucose counterregulation occurs in some insulin-dependent diabetic subjects (IDDMs) as a result of a combined deficiency of glucagon (IRG) and epinephrine (EPI) secretionin response to insulin-induced hypoglycemia. To determine whether the deficient glucagon response, the deficient epinephrine response, or both are manifestations of autonomic dysfunction, we used the pancreatic polypeptide (PP) secretory response to insulin-induced hypoglycemia as a marker for autonomic neuropathy.

Seven nondiabetic controls and 21 IDDMs were given insulin at 40 mU/kg/h after overnight euglycemia. Eight of the IDDMs had defective counterregulation (−CR), and 13 had adequate counterregulation (+ CR) by our previously published criteria. Those with −CR had a blunted EPI (δEPI = 102 ± 16 pg/ml; mean ± SEM) and PP (δPP = 12 ± 13 pg/ml) response as compared with controls (δEPI = 310 ± 49; δPP = 498 ± 43) and IDDMs with +CR (δEPI = 291 ± 32; δPP = 521 ± 86). In controls, IRG rose by 31 ± 6 pg/ml; in IDDMs, IRG failed to rise significantly above baselineregardless of counterregulatory status. Although the PP and EPI responses correlated well (r = 0.626, P < 0.001), the IRG response failed to correlate with either the EPI or the PP response.

We conclude that the deficient epinephrine, but not glucagon, secretory response to hypoglycemia in diabetic subjects is a result of autonomic neuropathy. The pancreatic polypeptide responsemay be helpful in evaluating the counterregulatory status of IDDMs before attempts at normalization of blood glucose using intensive therapeutic regimens, since a deficient pancreatic polypeptide response identifies patients with defective glucose counterregulation who have been shown previously to be at increased risk of severe hypoglycemia during intensive therapy.

  • Received October 15, 1984.
  • Revision received March 1, 1985.
  • Copyright © 1985 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

September 1985, 34(9)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Plasma Pancreatic Polypeptide Response to Insulin-induced Hypoglycemia as a Marker for Defective Glucose Counterregulation in Insulin-dependent Diabetes Mellitus
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Plasma Pancreatic Polypeptide Response to Insulin-induced Hypoglycemia as a Marker for Defective Glucose Counterregulation in Insulin-dependent Diabetes Mellitus
Neil H White, Ronald L Gingerich, Lucy A Levandoski, Philip E Cryer, Julio V Santiago
Diabetes Sep 1985, 34 (9) 870-875; DOI: 10.2337/diab.34.9.870

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Plasma Pancreatic Polypeptide Response to Insulin-induced Hypoglycemia as a Marker for Defective Glucose Counterregulation in Insulin-dependent Diabetes Mellitus
Neil H White, Ronald L Gingerich, Lucy A Levandoski, Philip E Cryer, Julio V Santiago
Diabetes Sep 1985, 34 (9) 870-875; DOI: 10.2337/diab.34.9.870
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Quantitative Assay for Human Cytoplasmic Islet Cell Antibodies
  • Effects of Fasting on Plasma Glucose and Prolonged Tracer Measurement of Hepatic Glucose Output in NIDDM
  • Calculated Pattern of Intraportal Insulin Appearance Without Independent Assessment of C-Peptide Kinetics
Show more Original Contribution

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.